TopFunds

Vertex Pharmaceuticals Incorporated

NASDAQ: VRTX

Stock price

499.74 USD

(+0%) TODAY

Biotechnology
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
(2.3)
(0.5)
1
8.1
4.5
10.3
9
12.8
13.9
(2.1)
15.3
-
02Free cash flow per share
(1.7)
0.7
2.3
4.5
5.7
11.4
9.3
15.1
12.6
(3.1)
12.4
-
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
1,032
1,702
2,489
3,048
4,163
6,206
7,574
8,931
9,869
11,020
12,075
27.9%
06% Change
-
-
-
-
-
-
-
-
-
-
-
27.9%
07Cost of revenue
(125.5)
(210.5)
(275.1)
(409.5)
(547.8)
(736.3)
(904.2)
(1,080)
(1,262)
(1,531)
(1,807)
30.6%
08Gross profit
906.8
1,492
2,214
2,638
3,615
5,469
6,670
7,850
8,607
9,490
10,268
27.5%
09% Margin
87.8%
87.6%
89%
86.6%
86.8%
88.1%
88.1%
87.9%
87.2%
86.1%
85%
87.3% A
10Operating expenses
(1,373)
(1,481)
(1,821)
(1,974)
(2,413)
(2,613)
(3,891)
(3,543)
(4,775)
(9,723)
(5,507)
14.9%
11% of Revenue
(133)%
(87)%
(73.2)%
(64.8)%
(58)%
(42.1)%
(51.4)%
(39.7)%
(48.4)%
(88.2)%
(45.6)%
(66.5)% A
12Operating Income
(468.7)
9.9
123.2
635.2
1,198
2,856
2,782
4,307
3,832
(232.9)
4,761
-
13Income tax expense
(30.4)
(16.7)
(107.3)
(1,487)
(218.1)
(405.2)
(388.3)
(910.4)
(760.2)
(784.1)
(690)
36.7%
14Net Income
(558.1)
(112.1)
263.5
2,097
1,177
2,712
2,342
3,322
3,620
(535.6)
3,953
-
15% Margin
(54.1)%
(6.6)%
10.6%
68.8%
28.3%
43.7%
30.9%
37.2%
36.7%
(4.9)%
32.7%
20.3% A
16Shares Outstanding
241.3
244.7
253.2
259.2
260.7
263.4
259.9
259.1
260.5
257.9
258
0.7%
17EPS Basic
(2.3)
(0.5)
1.1
8.3
4.6
10.4
9.1
13
14.1
(2.1)
15.5
-
18EPS Diluted
(2.3)
(0.5)
1
8.1
4.5
10.3
9
12.8
13.9
(2.1)
15.3
-
19EBITDA
(411.3)
75.5
103.3
706.8
1,560
3,285
2,918
4,436
4,605
486.3
4,866
-
% Margin
(39.8)%
4.4%
4.2%
23.2%
37.5%
52.9%
38.5%
49.7%
46.7%
4.4%
40.3%
23.8% A
20Net Interest Income (expense)
(84.2)
(81.4)
(57.5)
(34.1)
5.2
(36)
(56.6)
89.8
570.6
567.5
477.6
-
21Net Debt / EBITDA
(0.3)
(4.5)
(10.3)
(2.9)
(1.6)
(1.5)
(2)
(2.2)
(2.1)
(5.8)
(0.2)
(3) A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
714.8
1,184
1,665
2,650
3,109
5,988
6,795
10,504
10,369
4,570
5,088
21.7%
23Short-term investments
327.7
250.6
423.3
518.1
699
670.7
729.9
274.5
849.2
1,546
1,523
16.6%
24Accounts receivable
188.5
235.5
386
409.7
633.5
885.4
1,137
1,442
1,563
1,609
2,053
27%
25Other current assets
119
83.9
62.5
140.8
213.5
308.3
545.8
553.5
623.7
665.7
850.3
21.7%
26Inventory
56.1
77.6
111.8
124.4
167.5
280.8
353.1
460.6
738.8
1,205
1,687
40.6%
27Total Current Assets
1,407
1,832
2,649
3,843
4,823
8,133
9,561
13,235
14,144
9,596
11,201
23.1%
Non-Current Assets
28Net property, plant & equipment
697.7
698.4
789.4
812
833.3
1,284
1,424
1,456
1,453
2,585
3,083
16%
29Long-term investments
-
20.3
20.4
-
-
-
-
112.2
2,498
5,108
5,807
-
30Other non-current assets
393.7
346.6
87.2
1,591
2,662
2,334
2,448
3,348
4,635
5,244
6,052
31.4%
31Total Non-Current Assets
1,091
1,065
897.1
2,403
3,496
3,618
3,872
4,916
8,586
12,937
14,942
29.9%
Total Assets
2,497
2,894
3,546
6,246
8,319
11,752
13,433
18,151
22,730
22,533
26,143
26.5%
LIABILITIES
Current Liabilities
32Accounts payable
74.9
61.5
74
111
87.6
155.1
195
303.9
364.9
413
461.7
19.9%
33Short-term debt
86.8
319.4
22.5
5.3
38.8
42.4
80.2
89.4
83.7
92.3
82.8
(0.5)%
34Other current liabilities
344.4
411.7
710.7
1,004
1,208
1,680
1,867
2,349
3,099
3,059
3,317
25.4%
35Total Current Liabilities
506.2
792.5
807.3
1,120
1,335
1,878
2,142
2,742
3,547
3,565
3,861
22.5%
Non-Current Liabilities
36Long-term debt
739.4
521.3
583.9
581.6
622.9
889.5
887.2
810.3
724.7
1,657
3,800
17.8%
37Other non-current liabilities
159.4
244.7
112.5
108.9
275.5
298
303.3
685.8
877.7
901.8
(183.9)
-
38Total Non-Current Liabilities
898.8
766.1
696.4
690.4
898.4
1,188
1,191
1,496
1,602
2,559
3,616
14.9%
39Total Liabilities
1,405
1,559
1,504
1,811
2,233
3,065
3,333
4,238
5,150
6,124
7,477
18.2%
SHAREHOLDERS` EQUITY
40Common stock
2.4
2.5
2.5
2.5
2.6
2.6
2.5
2.6
2.6
2.6
2.5
0.3%
41Retained earnings / (deficit)
(5,262)
(5,374)
(5,120)
(2,990)
(1,853)
858.7
3,201
6,523
10,142
9,607
13,560
-
42Accumulated other comprehensive income / (loss)
1.8
21.2
(11.6)
0.7
(2)
(68.5)
15.9
0.8
(14.3)
127.8
(15.9)
-
43Noncontrolling interests
153.7
181.6
13.7
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
1,094
1,338
2,042
4,435
6,085
8,687
10,100
13,913
17,580
16,410
18,666
32.8%
45Total Liabilities and shareholders' Equity
2,497
2,894
3,546
6,246
8,319
11,752
13,433
18,151
22,730
22,533
26,143
26.5%
46Total Debt
826.2
840.8
606.4
586.8
661.7
931.9
967.4
899.7
808.4
1,750
3,883
16.7%
47Net Debt
111.5
(343.2)
(1,059)
(2,063)
(2,448)
(5,056)
(5,828)
(9,604)
(9,561)
(2,820)
(1,205)
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
(558.1)
(112.1)
263.5
2,097
1,177
2,712
2,342
3,322
3,620
(535.6)
3,953
-
49Depreciation & amortization
62.3
61.4
61.4
72.4
106.9
109.5
125.6
148.3
181.3
207.2
209.8
12.9%
50Share-based compensation expense
231
237.7
290.7
325
360.5
429.5
441.4
491.3
581.2
698.5
685.9
11.5%
51Changes in working capital and other assets
(100.7)
49.1
229.3
(1,224)
(74.9)
2.8
(265.6)
168.3
(844.8)
(862.7)
(1,218)
28.3%
52Net cash flows from operating activities
(365.4)
236.1
844.9
1,270
1,569
3,254
2,644
4,130
3,537
(492.6)
3,631
-
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(45.3)
(56.6)
(259.4)
(95.5)
(75.5)
(259.8)
(235)
(204.7)
(200.4)
(297.7)
(437.6)
25.5%
54Purchases of investments / marketable securities
(633)
(629.7)
(532.6)
(515.4)
(576.5)
(450.7)
(605.2)
(692.7)
(3,787)
(7,696)
(6,397)
26%
55Proceeds from maturities of marketable securities
1,067
757.6
369.2
431.6
570.9
809.9
499.3
920
934.2
4,466
5,913
18.7%
56Other investing activities
(120.2)
33.2
(14.9)
(22.8)
(1,154)
-
-
(343.7)
(89)
(241.7)
(24.7)
(14.6)%
57Net cash flows from investing activities
268.9
104.5
(437.7)
(202.2)
(1,235)
99.4
(340.9)
(321.1)
(3,142)
(3,770)
(945.4)
-
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
185.6
68.2
344.8
(60.7)
151.2
(274.2)
(1,323)
14.3
(293)
(1,063)
(1,890)
-
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
3.3
(6.9)
(284.7)
(12.5)
(29.1)
(29)
(18.7)
(85.5)
(44.9)
(33.6)
(5.4)
-
61Other financing activities
-
71.9
8.2
2.1
4.7
(202.1)
(135.9)
3.5
(224.3)
(398.8)
(366.2)
-
62Net cash flows from financing activities
188.9
133.3
68.4
(71.2)
126.8
(505.3)
(1,478)
(67.7)
(562.2)
(1,495)
(2,261)
-
63Increase (decrease) in cash and cash equivalents
89.5
469.2
481.5
990.7
462.4
2,868
811.2
3,712
(139.7)
(5,800)
515.6
19.1%
64Cash and equivalents, ending balance
714.8
1,184
1,665
2,658
3,121
5,989
6,800
10,512
10,372
4,572
5,088
21.7%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
(410.7)
179.5
585.5
1,175
1,494
2,994
2,409
3,925
3,337
(790.3)
3,194
-

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Vertex Pharmaceuticals Incorporated (VRTX) financial statements and performance

Explore Vertex Pharmaceuticals Incorporated (VRTX) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.